In the last trading session, 1.88 million Standard BioTools Inc (NASDAQ:LAB) shares changed hands as the company’s beta touched 1.58. With the company’s per share price at $1.26 changed hands at -$0.07 or -5.26% during last session, the market valuation stood at $469.04M. LAB’s last price was a discount, traded about -141.27% off its 52-week high of $3.04. The share price had its 52-week low at $1.17, which suggests the last value was 7.14% up since then.
Analysts gave the Standard BioTools Inc (LAB) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended LAB as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight. Standard BioTools Inc’s EPS for the current quarter is expected to be -0.03.
Standard BioTools Inc (NASDAQ:LAB) trade information
Instantly LAB was in red as seen at the end of in last trading. With action -10.00%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -28.00%, with the 5-day performance at -10.00% in the red. However, in the 30-day time frame, Standard BioTools Inc (NASDAQ:LAB) is -23.64% down.
The consensus price target for the stock as assigned by Wall Street analysts is 3.25, meaning bulls need an upside of 61.23% from its current market value. According to analyst projections, LAB’s forecast low is 3.25 with 3.25 as the target high. To hit the forecast high, the stock’s price needs a -157.94% plunge from its current level, while the stock would need to soar -157.94% for it to hit the projected low.
Standard BioTools Inc (LAB) estimates and forecasts
Year-over-year growth is forecast to reach 60.99% up from the last financial year.
Consensus estimates given by 3 financial analysts project the company’s revenue in the current quarter to hit an average of 43.03M. 2 analysts are of the opinion that Standard BioTools Inc’s revenue for the current quarter will be 45.6M. The company’s revenue for the corresponding quarters a year ago was 28.19M and 45.54M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 52.67%. The estimates for the next quarter sales put growth at 0.13%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 8.72%. The 2025 estimates are for Standard BioTools Inc earnings to increase by 62.06%, but the outlook for the next 5-year period is at 56.66% per year.
LAB Dividends
Standard BioTools Inc is expected to release its next quarterly earnings report in March.
VIKING GLOBAL INVESTORS LP holds the second largest percentage of outstanding shares, with 15.7524% or 58.65 million shares worth $103.81 million as of 2024-06-30.
